S-1/A: Onconetix Secures $25 Million Equity Line with Keystone Capital Partners, Files for Resale of Shares

Onconetix enters into a common stock purchase agreement with Keystone Capital Partners for up to $25 million, concurrently filing an amendment to its S-1 registration statement for the resale of up to 6,250,000 shares.

Summary

• Onconetix, Inc. has entered into a Common Stock Purchase Agreement with Keystone Capital Partners, LLC for up to $25 million.
• The agreement allows Onconetix to issue and sell shares of its common stock to Keystone from time to time.
• Keystone is obligated to purchase the shares, subject to certain conditions and limitations.
• Concurrently, Onconetix filed Amendment No. 1 to its Form S-1 registration statement to register the resale of up to 6,250,000 shares of common stock by Keystone.
• The actual number of shares issued will depend on the market price at the time of sale, but will not exceed 19.99% of the company's outstanding shares unless stockholder approval is obtained.
• The company will not receive any proceeds from the sale of common stock by the selling stockholder pursuant to this prospectus.
• The company may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus.
• The purchase price per share that Keystone will pay for shares of Common Stock purchased from us under the ELOC Purchase Agreement will fluctuate based on the market price of our shares at the time we elect to sell shares to Keystone and, further, to the extent that the Company sells shares of Common Stock under the ELOC Purchase Agreement, substantial amounts of shares could be issued and resold, which would cause dilution and may impact the Company's stock price.

Sentiment

Score: 6

Explanation: The announcement is neutral. While securing funding is positive, the potential dilution and market risks associated with the equity line temper the overall sentiment.

Positives

• The equity line provides Onconetix with access to capital, up to $25 million, to fund its operations.
• The agreement allows Onconetix flexibility in determining the timing and amount of sales of its common stock.
• The registration statement enables Keystone to resell the shares, providing liquidity for the investor.

Negatives

• The sale of shares to Keystone will result in dilution for existing Onconetix shareholders.
• The fluctuating purchase price based on market conditions could lead to uncertainty in the amount of capital raised.
• The company will not receive any proceeds from the sale of common stock by the selling stockholder pursuant to this prospectus.

Risks

• The market price of Onconetix's common stock could be negatively impacted by the potential resale of a large number of shares by Keystone.
• The company's ability to access the full $25 million under the agreement is subject to certain conditions and limitations.
• There is no guarantee that the company will be able to sell all of the shares registered for resale.
• The company may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus.

Future Outlook

The company may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.

Industry Context

Equity lines of credit are a common financing tool for small-cap companies, providing access to capital while allowing flexibility in managing dilution. The success of this arrangement will depend on Onconetix's ability to effectively deploy the capital and maintain investor confidence.

Stakeholder Impact

• Existing shareholders will experience dilution as a result of the issuance of new shares.
• The company's access to capital may benefit its employees and other stakeholders.
• The company's ability to execute its business plan may be enhanced by the availability of funding.

Next Steps

• Onconetix will file a prospectus supplement with the SEC.
• Onconetix may elect to sell shares of its common stock to Keystone from time to time, subject to market conditions and other factors.
• Keystone may resell the shares of common stock it purchases from Onconetix.

Key Dates

Keywords

Onconetix, Keystone Capital Partners, equity line of credit, common stock, resale, registration statement, dilution, ELOC Purchase Agreement